Tumor Biology

, Volume 35, Issue 10, pp 9523–9530 | Cite as

Role of epithelial to mesenchymal transition proteins in gynecological cancers: pathological and therapeutic perspectives

Review

Abstract

Gynecorelogic cancers like ovarian, cervical, and endometrial cancers are among the major threats to modern life, especially to female health. Like some other types of cancers, all of these gynecological cancers have found to be associated with the developmental stage epithelial to mesenchymal transition (EMT). More specifically, the aberrant expression of major EMT markers, such as lower expressions of E-cadherin and alpha-catenin, and overexpressions of N-cadherin, beta-catenin, vimentin, and matrix metalloproteinases, have been reported in ovarian, cervical, and endometrial cancers. The transcription factors, such as Twist, Snail, Slug, and Zeb, which regulate these EMT mediators, are also reported to be overexpressed in gynecological cancers. In addition to the over/lower expression, the promoter methylation of some of these genes has been identified too. In the era of target-specific cancer therapeutics, some promising studies showed that targeting EMT markers might be an interesting and successful tool in future cancer therapy. In this study, we have reviewed the recent development in the research on the association of EMT markers with three major gynecological cancers in the perspectives of carcinogenesis and therapeutics.

Keywords

Ovarian cancer Cervical cancer Endometrial cancer Epithelial to mesenchymal transitions Transcription factors Target-specific cancer therapy 

Notes

Conflicts of interest

None

References

  1. 1.
    Kong D, Li Y, Wang Z, Sarkar FH. Cancer stem cells and epithelial-to-mesenchymal transition (emt)-phenotypic cells: are they cousins or twins? Cancers (Basel). 2011;3:716–29.CrossRefGoogle Scholar
  2. 2.
    Larue L, Bellacosa A. Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3′ kinase/AKT pathways. Oncogene. 2005;24:7443–54.CrossRefPubMedGoogle Scholar
  3. 3.
    Khan MA, Chen HC, Zhang D, Fu J. Twist: a molecular target in cancer therapeutics. Tumour Biol. 2013;34:2497–506.CrossRefPubMedGoogle Scholar
  4. 4.
    Tania M, Khan MA, Fu J. Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer. Tumour Biol. 2014. doi: 10.1007/s13277-014-2163-y.PubMedGoogle Scholar
  5. 5.
    Yang G, Yuan J, Li K. EMT transcription factors: implication in osteosarcoma. Med Oncol. 2013;30:697.CrossRefPubMedGoogle Scholar
  6. 6.
    Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704–15.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Jeong HM, Kwon MJ, Shin YK. Overexpression of cancer-associated genes via epigenetic derepression mechanisms in gynecologic cancer. Front Oncol. 2014;4:12.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Piek JM, van Diest PJ, Verheijen RH. Ovarian carcinogenesis: an alternative hypothesis. Adv Exp Med Biol. 2008;622:79–87.CrossRefPubMedGoogle Scholar
  9. 9.
    Goff BA. Ovarian cancer: screening and early detection. Obstet Gynecol Clin N Am. 2012;39:183–94.CrossRefGoogle Scholar
  10. 10.
    Chobanian N, Dietrich 3rd CS. Ovarian cancer. Surg Clin N Am. 2008;88:285–99.CrossRefPubMedGoogle Scholar
  11. 11.
    Tania M, Khan MA, Song Y. Association of lipid metabolism with ovarian cancer. Curr Oncol. 2010;17:6–11.PubMedCentralPubMedGoogle Scholar
  12. 12.
    Morgan Jr RJ, Alvarez RD, Armstrong DK, et al. Epithelial ovarian cancer. J Natl Compr Canc Netw. 2011;9:82–113.PubMedGoogle Scholar
  13. 13.
    Colombo N, Carinelli S, Colombo A, et al. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;7(23 Suppl):vii27–32.Google Scholar
  14. 14.
    Canavan TP, Doshi NR. Cervical cancer. Am Fam Physician. 2000;61:1369–76.PubMedGoogle Scholar
  15. 15.
    Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011;378:1461–84.CrossRefPubMedGoogle Scholar
  16. 16.
    Jiang B, Xiao S, Khan MA, Xue M. Defective antioxidant systems in cervical cancer. Tumour Biol. 2013;34:2003–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Pessoa JN, Freitas AC, Guimaraes RA, et al. Endometrial assessment: when is it necessary? J Clin Med Res. 2014;6:21–5.PubMedCentralPubMedGoogle Scholar
  18. 18.
    Colombo N, Preti E, Landoni F, et al. Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;6(24 Suppl):vi33–8.Google Scholar
  19. 19.
    Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2095–128.CrossRefPubMedGoogle Scholar
  20. 20.
    Bakkum-Gamez JN, Gonzalez-Bosquet J, Laack NN, Mariani A, Dowdy SC. Current issues in the management of endometrial cancer. Mayo Clin Proc. 2008;83:97–112.CrossRefPubMedGoogle Scholar
  21. 21.
    Dittmer C, Katalinic A, Mundhenke C, Thill M, Fischer D. Epidemiology of vulvar and vaginal cancer in Germany. Arch Gynecol Obstet. 2011;284:169–74.CrossRefPubMedGoogle Scholar
  22. 22.
    Risinger JI, Berchuck A, Kohler MF, Boyd J. Mutations of the E-cadherin gene in human gynecologic cancers. Nat Genet. 1994;7:98–102.CrossRefPubMedGoogle Scholar
  23. 23.
    Lau MT, So WK, Leung PC. Fibroblast growth factor 2 induces E-cadherin down-regulation via PI3K/Akt/mTOR and MAPK/ERK signaling in ovarian cancer cells. PLoS One. 2013;8:e59083.PubMedCentralCrossRefPubMedGoogle Scholar
  24. 24.
    Sawada K, Mitra AK, Radjabi AR, et al. Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res. 2008;68:2329–39.PubMedCentralCrossRefPubMedGoogle Scholar
  25. 25.
    Myong NH. Loss of E-cadherin and acquisition of vimentin in epithelial-mesenchymal transition are noble indicators of uterine cervix cancer progression. Korean J Pathol. 2012;46:341–8.PubMedCentralCrossRefPubMedGoogle Scholar
  26. 26.
    Lee MY, Chou CY, Tang MJ, Shen MR. Epithelial-mesenchymal transition in cervical cancer: correlation with tumor progression, epidermal growth factor receptor overexpression, and snail up-regulation. Clin Cancer Res. 2008;14:4743–50.CrossRefPubMedGoogle Scholar
  27. 27.
    Tanaka Y, Terai Y, Kawaguchi H, et al. Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer. Cancer Biol Ther. 2013;14:13–9.PubMedCentralCrossRefPubMedGoogle Scholar
  28. 28.
    Schlosshauer PW, Ellenson LH, Soslow RA. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype. Mod Pathol. 2002;15:1032–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Lindberg ME, Stodden GR, King ML, et al. Loss of CDH1 and Pten accelerates cellular invasiveness and angiogenesis in the mouse uterus. Biol Reprod. 2013;89:8.PubMedCentralCrossRefPubMedGoogle Scholar
  30. 30.
    Park JH, Lee BI, Song ES, Whang SO, Lee WY, Cho SJ. Hypermethylation of E-cadherin in endometrial carcinoma. J Gynecol Oncol. 2008;19:241–5.PubMedCentralCrossRefPubMedGoogle Scholar
  31. 31.
    Huang RY, Wong MK, Tan TZ, et al. An EMT spectrum defines an anoikis-resistant and spheroidogenic intermediate mesenchymal state that is sensitive to e-cadherin restoration by a src-kinase inhibitor, saracatinib (AZD0530). Cell Death Dis. 2013;4:e915.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Comamala M, Pinard M, Thériault C, et al. Downregulation of cell surface CA125/MUC16 induces epithelial-to-mesenchymal transition and restores EGFR signalling in NIH:OVCAR3 ovarian carcinoma cells. Br J Cancer. 2011;104:989–99.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Lu JN, Lee WS, Yun JW, et al. Anthocyanins from Vitis coignetiae Pulliat Inhibit Cancer Invasion and Epithelial-Mesenchymal Transition, but these effects can be attenuated by tumor necrosis factor in human uterine cervical cancer HeLa cells. Evid Based Complement Alternat Med. 2013;2013:503043.PubMedCentralPubMedGoogle Scholar
  34. 34.
    Li BL, Lu W, Lu C, et al. CpG island hypermethylation-associated silencing of microRNAs promotes human endometrial cancer. Cancer Cell Int. 2013;13:44.PubMedCentralCrossRefPubMedGoogle Scholar
  35. 35.
    Tsuruta T, Kozaki K, Uesugi A, et al. miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res. 2011;71:6450–62.CrossRefPubMedGoogle Scholar
  36. 36.
    Fujimoto J, Ichigo S, Hirose R, Sakaguchi H, Tamaya T. Expression of E-cadherin and alpha- and beta-catenin mRNAs in ovarian cancers. Cancer Lett. 1997;115:207–12.CrossRefPubMedGoogle Scholar
  37. 37.
    Bullions LC, Notterman DA, Chung LS, Levine AJ. Expression of wild-type alpha-catenin protein in cells with a mutant alpha-catenin gene restores both growth regulation and tumor suppressor activities. Mol Cell Biol. 1997;17:4501–8.PubMedCentralPubMedGoogle Scholar
  38. 38.
    Wang J, Ou J, Guo Y, et al. TBLR1 is a novel prognostic marker and promotes epithelial-mesenchymal transition in cervical cancer. Br J Cancer. 2014;111:112–24.PubMedCentralCrossRefPubMedGoogle Scholar
  39. 39.
    Fujimoto J, Ichigo S, Hori M, Morishita S, Tamaya T. Progestins and danazol effect on cell-to-cell adhesion, and E-cadherin and alpha- and beta-catenin mRNA expressions. J Steroid Biochem Mol Biol. 1996;57:275–82.CrossRefPubMedGoogle Scholar
  40. 40.
    Carico E, Atlante M, Giarnieri E, et al. E-cadherin and alpha-catenin expression in normal, hyperplastic and neoplastic endometrium. Anticancer Res. 2010;30:4993–7.PubMedGoogle Scholar
  41. 41.
    Bodnar L, Stanczak A, Cierniak S, et al. Wnt/β-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res. 2014;7:16.PubMedCentralCrossRefPubMedGoogle Scholar
  42. 42.
    Mao Y, Xu J, Li Z, Zhang N, Yin H, Liu Z. The role of nuclear β-catenin accumulation in the Twist2-induced ovarian cancer EMT. PLoS One. 2013;8:e78200.PubMedCentralCrossRefPubMedGoogle Scholar
  43. 43.
    Rampias T, Boutati E, Pectasides E, et al. Activation of Wnt signaling pathway by human papillomavirus E6 and E7 oncogenes in HPV16-positive oropharyngeal squamous carcinoma cells. Mol Cancer Res. 2010;8:433–43.CrossRefPubMedGoogle Scholar
  44. 44.
    van der Zee M, Jia Y, Wang Y, et al. Alterations in Wnt-β-catenin and Pten signalling play distinct roles in endometrial cancer initiation and progression. J Pathol. 2013;230:48–58.CrossRefPubMedGoogle Scholar
  45. 45.
    Zhou X, Hu Y, Dai L, et al. MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer. PLoS One. 2014;9:e96718.PubMedCentralCrossRefPubMedGoogle Scholar
  46. 46.
    Jung S, Yi L, Kim J, et al. The role of vimentin as a methylation biomarker for early diagnosis of cervical cancer. Mol Cells. 2011;31:405–11.PubMedCentralCrossRefPubMedGoogle Scholar
  47. 47.
    Subramaniam KS, Tham ST, Mohamed Z, et al. Cancer-associated fibroblasts promote proliferation of endometrial cancer cells. PLoS One. 2013;8:e68923.PubMedCentralCrossRefPubMedGoogle Scholar
  48. 48.
    Karam A, Dorigo O. MMPs in ovarian cancer as therapeutic targets. Anticancer Agents Med Chem. 2012;12:764–72.CrossRefPubMedGoogle Scholar
  49. 49.
    Basu M, Mukhopadhyay S, Chatterjee U, Roy SS. FGF16 promotes invasive behavior of SKOV-3 ovarian cancer cells through activation of mitogen-activated protein kinase (MAPK) signaling pathway. J Biol Chem. 2014;289:1415–28.PubMedCentralCrossRefPubMedGoogle Scholar
  50. 50.
    da Silva Cardeal LB, Brohem CA, Corrêa TC, et al. Higher expression and activity of metalloproteinases in human cervical carcinoma cell lines is associated with HPV presence. Biochem Cell Biol. 2006;84:713–9.CrossRefPubMedGoogle Scholar
  51. 51.
    Kaewprag J, Umnajvijit W, Ngamkham J, Ponglikitmongkol M. HPV16 oncoproteins promote cervical cancer invasiveness by upregulating specific matrix metalloproteinases. PLoS One. 2013;8:e71611.PubMedCentralCrossRefPubMedGoogle Scholar
  52. 52.
    Van Themsche C, Mathieu I, Parent S, Asselin E. Transforming growth factor-beta3 increases the invasiveness of endometrial carcinoma cells through phosphatidylinositol 3-kinase-dependent up-regulation of X-linked inhibitor of apoptosis and protein kinase c-dependent induction of matrix metalloproteinase-9. J Biol Chem. 2007;282:4794–802.CrossRefPubMedGoogle Scholar
  53. 53.
    Hosono S, Kajiyama H, Terauchi M, et al. Expression of Twist increases the risk for recurrence and for poor survival in epithelial ovarian carcinoma patients. Br J Cancer. 2007;96:314–20.PubMedCentralCrossRefPubMedGoogle Scholar
  54. 54.
    Yeasmin S, Nakayama K, Rahman MT, et al. Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition. Int J Cancer. 2011;128:94–104.CrossRefPubMedGoogle Scholar
  55. 55.
    Yin G, Alvero AB, Craveiro V, et al. Constitutive proteasomal degradation of TWIST-1 in epithelial-ovarian cancer stem cells impacts differentiation and metastatic potential. Oncogene. 2013;32:39–49.PubMedCentralCrossRefPubMedGoogle Scholar
  56. 56.
    Wang T, Li Y, Tuerhanjiang A, et al. Correlation of Twist upregulation and senescence bypass during the progression and metastasis of cervical cancer. Front Med. 2014;8:106–12.CrossRefPubMedGoogle Scholar
  57. 57.
    Missaoui N, Hmissa S, Trabelsi A, et al. Promoter hypermethylation of CDH13, DAPK1 and TWIST1 genes in precancerous and cancerous lesions of the uterine cervix. Pathol Res Pract. 2011;207:37–42.CrossRefPubMedGoogle Scholar
  58. 58.
    Li J, Zhou BP. Activation of β-catenin and Akt pathways by Twist are critical for the maintenance of EMT associated cancer stem cell-like characters. BMC Cancer. 2011;11:49.PubMedCentralCrossRefPubMedGoogle Scholar
  59. 59.
    Feng Z, Gan H, Cai Z, et al. Aberrant expression of hypoxia-inducible factor 1α, TWIST and E-cadherin is associated with aggressive tumor phenotypes in endometrioid endometrial carcinoma. Jpn J Clin Oncol. 2013;43:396–403.CrossRefPubMedGoogle Scholar
  60. 60.
    Dong P, Kaneuchi M, Xiong Y, et al. Identification of KLF17 as a novel epithelial to mesenchymal transition inducer via direct activation of TWIST1 in endometrioid endometrial cancer. Carcinogenesis. 2014;35:760–8.CrossRefPubMedGoogle Scholar
  61. 61.
    Jin H, Yu Y, Zhang T, et al. Snail is critical for tumor growth and metastasis of ovarian carcinoma. Int J Cancer. 2010;126:2102–11.PubMedGoogle Scholar
  62. 62.
    Cheng JC, Chang HM, Leung PC. Egr-1 mediates epidermal growth factor-induced downregulation of E-cadherin expression via Slug in human ovarian cancer cells. Oncogene. 2013;32:1041–9.CrossRefPubMedGoogle Scholar
  63. 63.
    Yuan H, Kajiyama H, Ito S, et al. ALX1 induces snail expression to promote epithelial-to-mesenchymal transition and invasion of ovarian cancer cells. Cancer Res. 2013;73:1581–90.CrossRefPubMedGoogle Scholar
  64. 64.
    Lu ZY, Dong R, Li D, et al. SNAI1 overexpression induces stemness and promotes ovarian cancer cell invasion and metastasis. Oncol Rep. 2012;27:1587–91.PubMedGoogle Scholar
  65. 65.
    Chen Z, Li S, Huang K, et al. The nuclear protein expression levels of SNAI1 and ZEB1 are involved in the progression and lymph node metastasis of cervical cancer via the epithelial-mesenchymal transition pathway. Hum Pathol. 2013;44:2097–105.CrossRefPubMedGoogle Scholar
  66. 66.
    Liu XF, Yang WT, Xu R, Liu JT, Zheng PS. Cervical cancer cells with positive Sox2 expression exhibits the properties of cancer stem cells. PLoS One. 2014;9:e87092.PubMedCentralCrossRefPubMedGoogle Scholar
  67. 67.
    Hipp S, Walch A, Schuster T, et al. Activation of epidermal growth factor receptor results in snail protein but not mRNA overexpression in endometrial cancer. J Cell Mol Med. 2009;13:3858–67.PubMedCentralCrossRefPubMedGoogle Scholar
  68. 68.
    Supernat A, Lapinska-Szumczyk S, Majewska H, et al. Epithelial-mesenchymal transition and cancer stem cells in endometrial cancer. Anticancer Res. 2013;33:5461–9.PubMedGoogle Scholar
  69. 69.
    Kurrey NK, Jalgaonkar SP, Joglekar AV, et al. Snail and slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells. 2009;7:2059–68.CrossRefGoogle Scholar
  70. 70.
    Zhao L, Chen W, Taylor KM, Cai B, Li X. LIV-1 suppression inhibits HeLa cell invasion by targeting ERK1/2-Snail/Slug pathway. Biochem Biophys Res Commun. 2007;363:82–8.CrossRefPubMedGoogle Scholar
  71. 71.
    Saegusa M, Hashimura M, Kuwata T, Okayasu I. Requirement of the Akt/beta-catenin pathway for uterine carcinosarcoma genesis, modulating E-cadherin expression through the transactivation of slug. Am J Pathol. 2009;174:2107–15.PubMedCentralCrossRefPubMedGoogle Scholar
  72. 72.
    Bendoraite A, Knouf EC, Garg KS, et al. Regulation of miR-200 family microRNAs and ZEB transcription factors in ovarian cancer: evidence supporting a mesothelial-to-epithelial transition. Gynecol Oncol. 2010;116:117–25.PubMedCentralCrossRefPubMedGoogle Scholar
  73. 73.
    Wellner U, Schubert J, Burk UC, et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs. Nat Cell Biol. 2009;11:1487–95.CrossRefPubMedGoogle Scholar
  74. 74.
    Chen D, Zhang Y, Wang J, et al. MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J Ovarian Res. 2013;6:50.PubMedCentralCrossRefPubMedGoogle Scholar
  75. 75.
    Tai CJ, Cheng CW, Su HY, et al. Thrombomodulin mediates the migration of cervical cancer cells through the regulation of epithelial-mesenchymal transition biomarkers. Tumour Biol. 2014;35:47–54.CrossRefPubMedGoogle Scholar
  76. 76.
    Cochrane DR, Howe EN, Spoelstra NS, Richer JK. Loss of miR-200c: a marker of aggressiveness and chemoresistance in female reproductive cancers. J Oncol. 2010;2010:821717.PubMedCentralCrossRefPubMedGoogle Scholar
  77. 77.
    Pils S, Joura EA, Winter MP, Shrestha A, Jaeger-Lansky A, Ott J. What do women with gynecologic cancer know about HPV and their individual disease? A pilot study. BMC Cancer. 2014;14:388.PubMedCentralCrossRefPubMedGoogle Scholar
  78. 78.
    Wang WS, Yang XS, Xia M, Jiang HY, Hou JQ. Silencing of twist expression by RNA interference suppresses epithelial-mesenchymal transition, invasion, and metastasis of ovarian cancer. Asian Pac J Cancer Prev. 2012;13:4435–9.CrossRefPubMedGoogle Scholar
  79. 79.
    Su JL, Chen PB, Chen YH, et al. Downregulation of microRNA miR-520h by E1A contributes to anticancer activity. Cancer Res. 2010;70:5096–108.PubMedCentralCrossRefPubMedGoogle Scholar
  80. 80.
    Zhu K, Chen L, Han X, Wang J, Wang J. Short hairpin RNA targeting Twist1 suppresses cell proliferation and improves chemosensitivity to cisplatin in HeLa human cervical cancer cells. Oncol Rep. 2012;27:1027–34.PubMedCentralPubMedGoogle Scholar
  81. 81.
    Bing L, Hong C, Li-Xin S, Wei G. MicroRNA-543 suppresses endometrial cancer oncogenicity via targeting FAK and TWIST1 expression. Arch Gynecol Obstet. 2014;290:533–41.CrossRefPubMedGoogle Scholar
  82. 82.
    Dong P, Kaneuchi M, Watari H, Sudo S, Sakuragi N. MicroRNA-106b modulates epithelial-mesenchymal transition by targeting TWIST1 in invasive endometrial cancer cell lines. Mol Carcinog. 2014;53:349–59.CrossRefPubMedGoogle Scholar
  83. 83.
    Khan MA, Yang M, Wei C, Gan L, Fu J. Thymoquinone downregulates n-cadherin, twist and snail expression and inhibits migration and invasion in cancer cells. Proceedings of Annual meeting of American Association of Cancer Research; San Diego, USA, 5–9 April 2014.Google Scholar
  84. 84.
    Jin HY, Feng YJ. Inhibitory effects of antisense Snail on invasion and migration of ovarian carcinoma cells. Zhonghua Fu Chan Ke Za Zhi. 2005;40:400–3.PubMedGoogle Scholar
  85. 85.
    Chu Q, Ling MT, Feng H, et al. A novel anticancer effect of garlic derivatives: inhibition of cancer cell invasion through restoration of E-cadherin expression. Carcinogenesis. 2006;27:2180–9.CrossRefPubMedGoogle Scholar
  86. 86.
    Khan MA, Chen HC, Wan XX, et al. Regulatory effects of resveratrol on antioxidant enzymes: a mechanism of growth inhibition and apoptosis induction in cancer cells. Mol Cells. 2013;35:219–25.PubMedCentralCrossRefPubMedGoogle Scholar
  87. 87.
    Baribeau S, Chaudhry P, Parent S, Asselin É. Resveratrol inhibits cisplatin-induced epithelial-to-mesenchymal transition in ovarian cancer cell lines. PLoS One. 2014;9:e86987.PubMedCentralCrossRefPubMedGoogle Scholar
  88. 88.
    Lam SS, Mak AS, Yam JW, Cheung AN, Ngan HY, Wong AS. Targeting estrogen-related receptor alpha inhibits epithelial-to-mesenchymal transition and stem cell properties of ovarian cancer cells. Mol Ther. 2014;22:743–51.PubMedCentralCrossRefPubMedGoogle Scholar
  89. 89.
    Haslehurst AM, Koti M, Dharsee M, et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer. 2012;12:91.PubMedCentralCrossRefPubMedGoogle Scholar
  90. 90.
    Wang P, Chen J, Mu LH, Du QH, Niu XH, Zhang MY. Propofol inhibits invasion and enhances paclitaxel-induced apoptosis in ovarian cancer cells through the suppression of the transcription factor slug. Eur Rev Med Pharmacol Sci. 2013;17:1722–9.PubMedGoogle Scholar
  91. 91.
    Zhao W, Zhou Y, Xu H, Cheng Y, Kong B. Snail family proteins in cervical squamous carcinoma: expression and significance. Clin Invest Med. 2013;36:E223–33.PubMedGoogle Scholar
  92. 92.
    Chung MT, Lai HC, Sytwu HK, et al. SFRP1 and SFRP2 suppress the transformation and invasion abilities of cervical cancer cells through Wnt signal pathway. Gynecol Oncol. 2009;112:646–53.CrossRefPubMedGoogle Scholar
  93. 93.
    Chang B, Kim J, Jeong D. Klotho inhibits the capacity of cell migration and invasion in cervical cancer. Oncol Rep. 2012;28:1022–8.PubMedGoogle Scholar
  94. 94.
    Nakamura K, Kodama J, Hongo A, Hiramatsu Y. Role of emmprin in endometrial cancer. BMC Cancer. 2012;12:191.PubMedCentralCrossRefPubMedGoogle Scholar
  95. 95.
    Huszar M, Pfeifer M, Schirmer U, et al. Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. J Pathol. 2010;220:551–61.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Gynaecolgy and ObstetricsShenzhen FuTian District Traditional Chinese Medicine HospitalShenzhenChina
  2. 2.Department of Gynaecolgy and ObstetricsMaternal and Child Health Care HospitalShenzhenChina

Personalised recommendations